MetaVia Inc. (MTVA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.62−$0.0090 (−0.55%) on the dayAs of the close; data may be delayed.
MTVA price, last 12 months
Key stats
- Previous close
- $1.63
- Open
- $1.66
- Day range
- $1.61 – $1.68
- 52-week range
- $0.9661 – $14.85
- Volume
- 25.4K
- Avg volume (20 days)
- 85.3K
- Market cap
- $10.9M
Performance
1W−6.3%
1M−3.5%
3M+13.4%
6M+22.8%
YTD−80.8%
1Y−86.0%
vs S&P 500, 1Y−102.8 pts
Technicals and fundamentals
About MetaVia Inc.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $10.9M